- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03431688
Tailored Therapy for Clarithromycin-Resistant H. Pylori
March 5, 2019 updated by: Shin, Woon Geon, Kangdong Sacred Heart Hospital
Efficacy Comparison of Metronidazole-based Triple and Bismuth-based Quadruple Therapy for Clarithromycin Resistant-Helicobacter Pylori Infection: Randomized Controlled Trial
Clarithromycin-resistant H. pylori is the main cause of H. pylori eradication failure.
Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has been studied recently, however, there have been few studies comparing treatment regimen in patient with clarithromycin-resistant H. pylori.
We used sequencing-based clarithromycin resistance mutation and aimed to compare PAM (proton pump inhibitor, amoxicilline, metronidazole) regimen and PBMT (proton pump inhibitor, bismuth, metronidazole, tetracyclin) regimen in patient with clarithromycin-resistant H. pylori.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
660
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Woon Geon Shin
- Phone Number: 82-2-2225-2814
- Email: sgun9139@gmail.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 134-701
- Recruiting
- Kangdong Sacred Heart Hospital
-
Contact:
- Woon Geon Shin, MD
- Phone Number: 82-2-2225-2814
- Email: sgun9139@gmail.com
-
Principal Investigator:
- Woon Geon Shin, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- peptic ulcer disease
- H. pylori gastritis
- low grade MALT lymphoma
Exclusion Criteria:
- history of gastric cancer surgery
- severe comorbidity (ESRD, LC)
- hypersensitivity to drug
- pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: PAM
treatment with PPI, metonidazole, amoxicillin
|
treatment with PPI, metonidazole, amoxicillin
|
ACTIVE_COMPARATOR: PBMT
treatment with PPI, metonidazole, bismuth, tetracyclin
|
treatment with PPI, metonidazole, bismuth, tetracyclin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
H. pylori eradication rate
Time Frame: 14 days
|
H. pylori eradication rate
|
14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 1, 2018
Primary Completion (ANTICIPATED)
December 30, 2020
Study Completion (ANTICIPATED)
December 30, 2020
Study Registration Dates
First Submitted
January 31, 2018
First Submitted That Met QC Criteria
February 12, 2018
First Posted (ACTUAL)
February 13, 2018
Study Record Updates
Last Update Posted (ACTUAL)
March 6, 2019
Last Update Submitted That Met QC Criteria
March 5, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KangdongSHH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helicobacter Pylori Infection
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingHelicobacter Pylori Infection | Helicobacter Pylori EradicationBangladesh
-
Shandong UniversityRecruitingHelicobacter Pylori Infection | Patient Education | Helicobacter Pylori EradicationChina
-
Shandong UniversityCompletedHelicobacter Pylori Infection Helicobacter Pylori Eradication Patient EducationChina
-
Shanghai Jiao Tong University School of MedicineCompletedCure Rate of Helicobacter Pylori InfectionChina
-
Seoul National University Bundang HospitalRecruitingHelicobacter Pylori Infection | Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation | Helicobacter Pylori Associated Gastrointestinal Disease | Helicobacter Pylori Infection, Susceptibility toKorea, Republic of
-
The First Affiliated Hospital of Nanchang UniversityUnknownBacterial Infection Due to Helicobacter Pylori (H. Pylori) | Eradication Therapy of Helicobacter Pylori | Detection of Helicobacter PyloriChina
-
Tanta UniversityNot yet recruitingPersistent Helicobacter Pylori InfectionEgypt
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedHelicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)Helicobacter Pylori Infection | Helicobacter Pylori gyrA Levofloxacin Resistance Mutation | Fecal Drug Resistance Gene Detection | Helicobacter Pylori Infection, Susceptibility toChina
-
National University Hospital, SingaporeUnknownHELICOBACTER PYLORI INFECTIONSSingapore
-
Kaohsiung Veterans General Hospital.Kaohsiung Medical University Chung-Ho Memorial HospitalCompletedHelicobacter Pylori InfectionTaiwan
Clinical Trials on PAM
-
Centre Jean PerrinRoche Pharma AG; NanoString Technologies, Inc.Terminated
-
The Miriam HospitalUniversity of California, Berkeley; National Heart, Lung, and Blood Institute... and other collaboratorsCompletedSmoking Cessation | AsthmaUnited States
-
Dana-Farber Cancer InstituteNanoString Technologies, Inc.Active, not recruiting
-
Dana-Farber Cancer InstituteNanoString Technologies, Inc.Active, not recruiting
-
Nationwide Children's HospitalAmerican Heart AssociationCompleted
-
Pomeranian Medical University SzczecinCharite University, Berlin, Germany; Imperial College London; SANPROBI SPOLKA... and other collaboratorsRecruitingHealthy | Stress | Dietary SupplementPoland
-
National Institute of Allergy and Infectious Diseases...RecruitingCystic Fibrosis | Bacterial Disease CarrierUnited States
-
Atrium Medical CenterMaastricht University; ZonMw: The Netherlands Organisation for Health Research...UnknownIntermittent ClaudicationNetherlands
-
Washington University School of MedicineCompletedMelanoma | Pigmented Skin LesionUnited States
-
Medical University of South CarolinaCompletedWeight Loss | Dementia, Alzheimer TypeUnited States